| Name | Title | Contact Details |
|---|
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.
Our emtelliPro NLP engine transforms difficult-to-use, narrative medical text into valuable and actionable insights. Enable innovation. Improve competitiveness. Drive performance.
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare and orphan diseases.
Red Light Holland`s goal is to, over time, help make the relatively unknown `magic truffle` a familiar name across the world. We are currently setting up to grow, distribute and market a premium brand of magic truffles to the legal, recreational market within the Netherlands, and we can`t wait to shift the existing paradigm to direct further attention to the legal and responsible use of magic truffles.
Essential Formulas is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.